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A NOVEL CARDIAC PACING PARADIGM FOR ATRIAL FIBRILLATION
AND HEART FAILURE PATIENTS

GEORGE EMANUEL YANULIS

ABSTRACT

It has been estimated that 4.6 million persons have heart failure, and 400,000
to 700,000 new cases develop each year and the U.S. Hospital discharges for
HF rose from 399,000 in 1979 to 1,099,000 in 2004 according to the National
Hospital Discharge Survey. Atrial fibrillation is the most common sustained
cardiac arrhythmia in the United States. Recent studies have demonstrated that
ventricular rate control is a viable treatment strategy for patients in atrial
fibrillation.
In a number of cases, despite the electrical resynchronization of the ventricles
using biventricular pacing (cardiac resynchronization therapy), heart failure
patients in sinus rhythm do not respond to cardiac resynchronization therapy as
with other heart failure patients. These non-responders may respond to our
pacing paradigm which is the combined use of cardiac resynchronization therapy
which is commonly designated as CRT and coupled pacing (CP) which will be
referred to as CRT+CP.
Using a custom “Y”-lead adapter, an unmodified dual chamber clinical
pacemaker can be used to achieve almost any combination of an experimental
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stimulation paradigm. And by using the asynchronous mode of a dual chamber
pacemaker, the ventricles can be paced at rates sufficient to produce heart
failure (180 to 240 beats per minute) which had been successfully accomplished
as part of the research protocol in our coupled pacing paradigm studies. These
specially designed Y connectors facilitated our coupled pacing and biventricular
pacing paradigm studies, i.e. allowed us to induce AF and apply CP under
experimental conditions.
My research on this novel pacing paradigm (CRT+CP) has shown that it
slowed the contractile rate by half (116±16 cycles per minute vs. 259±15 cycles
per minute). And CRT+CP as compared with CRT at a similar contractile rate
(CRT-vagal stimulation at 103±14 cycles per minute) also dramatically increased
both the diastolic period (48±6% vs. 27±3%, p=0.02) and the left ventricular
ejection fraction (51±10% vs. 25±4%, p<0.001) as well.
This research has further demonstrated that the addition of a coupled paced
beat significantly increased the left ventricular strain. The addition of coupled
pacing to biventricular pacing also improved the left ventricular ejection (51 ±
10%) to that of sinus rhythm despite the continual acute atrial fibrillation. CP may
be combined with biventricular pacing (CRT+CP) to slow the ventricular rate of
mechanical contractions and further improve contractility to a greater extent than
what has been observed by CRT alone in patients with dyssynchronized heart
failure and atrial fibrillation.
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CHAPTER I
Introduction to Coupled Pacing (CP) and CP with CRT

1.1

Overview
The 5-year mortality of patients newly diagnosed with chronic heart failure

(CHF) is 50%, despite the best of medical efforts [1]. Approximately 15-30% of
heart failure patients are in concurrent atrial fibrillation (AF) [1]. At least 25% of
heart failure patients develop major left ventricular conduction abnormalities.
Last year 200,000 patients in the USA alone receive defibrillators at a cost of
over $20,000 per unit. Hospital cost per implantation is currently set at a cost of
approximately $10,000 [1]. These numbers are growing at an annual rate of 1520%. As the U.S. population ages, the incidence and prevalence of CHF are
expected to dramatically increase according to Gregg C. Fonarow, MD (Director
of the Ahmanson-UCLA Cardiomyopathy Center). He also articulated that CHF is
the primary diagnosis for 875,000 hospitalizations annually, and it is the most
common diagnosis among hospitalized patients 65 years of age or older.
Fonarow further articulated that CHF had been the primary cause of death in
approximately 250 000 people per year in 2001 [2]. Hospital discharges for CHF
increased from 399,000 in 1979 to 1,099,000 in 2004 an increase of 175%
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(NHDS and NHLBI). The estimated direct and indirect cost of CHF in the United
States for 2007 is $33.2 billion [1]. In 2001, $4.0 billion ($5912 per discharge) was
paid to Medicare beneficiaries for CHF [1] .The prevalence and incidence of heart
failure and hospital discharges associated with this disease demonstrates the
need for several life-style changes in order to decrease the increasing trends in
this cardiovascular disease entity [2].
1.2

Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the

United States [3]. By increasing ventricular rate, AF can cause a tachycardiamediated cardiomyopathy. Previous work [4] has shown that when sinus rhythm
can not be restored, ventricular rate control is a viable treatment option. For the
last several years, our laboratory has been investigating the implementation of
coupled pacing (CP) [5-8], a novel pacing paradigm, for controlling ventricular rate
of mechanical contraction (VRMC). CP involves application of electrical stimuli to
the ventricles after the effective refractory period. VRMC reduction by CP is the
result of blocked conduction of rapid supra-ventricular activations to the ventricles
during AF. We propose a new pacing regimen which is a combined therapy of
CRT and CP. Rather than the CRT ending during episodes of AF, the new pacing
regimen could be applied. Briefly, (CRT+CP) will be applied as follows: the 1st
stimuli will be applied to the left ventricle and the 2nd stimuli to the right ventricle
simultaneously in the same manner as CRT is used clinically today. Thus, these
first 2 stimulations will result in a more synchronized electrical activation and
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subsequent contraction of both ventricles. We will then apply a 3rd premature
paced beat to activate both ventricles electrically but not mechanically. This 3rd
paced beat to CRT will 1) block rapid supra-ventricular activation of the ventricles
during AF, causing the ventricles to contract at a slower rate and 2) provide
positive inotropic support [9] in a similar manner as we found for CP [5-8].
Electrical activity in the heart is spontaneously generated by the SA node which is
also designated as the physiological pacemaker. This electrical impulse is
propagated throughout the right atrium, and through Bachman's Bundle to the left
atrium, stimulating the myocardium of the atria to contract [10]. The conduction of
the electrical impulse continues throughout the atria is seen on the ECG as the P
wave. As the electrical activity is spreading throughout the atria, it travels via
specialized pathways, known as internodal tracts, from the SA node to the AV
node. This latter node functions as a critical delay in the conduction system
Biventricular pacing also known as cardiac resynchronization therapy (CRT) is
for the most part an effective pacing therapy in restoring a more uniform electrical
activation and contractile performance in heart failure (HF) patients who are in
sinus rhythm but have ventricular conduction system disturbances [11]. The
pacemakers which are used in CRT follow the NASPE designation of pacing
codes. Although CRT is effective in many HF patients with LBBB, CRT is not
effective in some HF patients despite resynchronization (non-responders) even
during sinus rhythm. CRT can only be effective if the ventricular rate is controlled
during AF. If CP is added to CRT, this could be an effective means of rate control.

3

Today’s cardiac pacemakers that perform CRT generally sense atrial activity
and also track their rate. After sensing atrial activation, the device paces both
ventricles at a shortened atrioventricular interval in order to insure that the
ventricles are activated more uniformly by the biventricular pacing. However, if the
rate of atrial activation suddenly increases or the atria fibrillate (paroxysmal AF),
these pacemakers automatically will end atrial tracking and mode shut off. That
is, when their upper atrial tracking rate is exceeded, the biventricular pacing is
shut off. Therefore, the beneficial effect of CRT is lost until the episode of AF ends
and CRT can resume.
1.3

Research Aims
For the past 3 years, Dr. Wallick and I have been studying a novel pacing

modality called coupled pacing (CP) which is designed to improve cardiac function
during atrial fibrillation (AF) and heart failure [8,12,13]. This pacing therapy both
slows the rate of ventricular contraction and increases contractility.

CP first

senses the intrinsic electrical activation of the heart. Then a delayed stimulation
coupled to this intrinsic activation is applied, resulting in a second electrical
activation with minimal mechanical contraction. However, the secondary electrical
activation causes the subsequent intrinsic activation to result in a stronger
contraction.
The rationale for the use of the canine as the animal model for our cardiac
pacing research study for the evaluation of the CRT and CRT and CRT+CP is
based on the similar anatomical and physiological similarities which exist between
the canine and human cardiovascular systems [14] The canine model is a well-
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established model for studying AF and HF [15] The dogs are large enough that
pacemakers and their leads could be implanted.

Additionally, the dog has a

similar heart rate to that of a human. Another important reason for the use of
dogs is the ability to monitor them in the conscious state. Finally, dogs are robust
experimental animals and this helps assure success for our proposed
experiments.

1.3.1 Experimental Paradigm for AF
Protocols for producing experimental heart failure by rapid ventricular pacing
are well established [16,17]; however, for safety reasons, commonly used clinical
pacemakers do not allow pacing rates that are sufficient to induce either heart
failure (HF) or atrial fibrillation (AF). In chapter 2, the experimental protocol for
establishing AF using standard dual chambered cardiac pacemakers [12] will be
discussed. More specifically rapid ventricular pacing was achieved by modifying
a single-chamber pacemaker. In this study [12], we describe the use of a dualchamber pacemaker and a custom “Y”-lead adapter (Figure 1), and we show
how rapid pacing can be achieved without the need to modify the circuitry or
programming of a standard clinical pacemaker.
In a similar manner, experimental atrial fibrillation has been previously
induced by the use of rapid atrial pacing [12]. Because of the shorter refractory
period of atrial tissue, the pacing rate needs to be very rapid (400 to 600 bpm) to
induce AF. Although specially modified clinical pacemakers have been built for
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the purpose of induction of chronic atrial fibrillation, the method described as
follows facilitates AF induction without the need for pacemaker modification [12].

1.3.2 Coupled Pacing
In chapter 3, my studies [13] using sustained coupled pacing will be
discussed. Coupled pacing has both a negative chronotropic effect (decreases
the heart rate) and as a positive inotropic effect (increases the myocardial
contractility). Our research to date has demonstrated that the addition of a
coupled paced beat significantly increased left ejection fraction (LVEF), and the
1st derivative of left ventricular pressure development (LVdP/dt), and the left
ventricular strain [8,12,13] which improves overall myocardial performance in HF
and AF patients. In Chapter 3, I will also discuss how the use of coupled pacing
(CP) and how it dramatically reverses the effects of persistent atrial fibrillation on
the left ventricle [8].

1.3.3 CRT + CP Pacing
In Chapter 4, I will discuss how the addition of coupled paced beat to
biventricular pacing improved the left ventricular ejection at a level which is
comparable to that of sinus rhythm despite the continual acute atrial fibrillation
occurring.
This chapter will also discuss how CP may be combined with biventricular
pacing (CRT+CP) to slow the ventricular rate of mechanical contractions and
further improve contractility to a greater extent than what has been observed by
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CRT alone in patients with dyssynchronized heart failure and atrial fibrillation
[13]. And by controlling the time delay of the application of CP, one can balance
the negative chronotropic vs. positive inotropic effects of this pacing therapy in a
manner that provides the most judicious treatment for each patient. With the
development of modern sensing capabilities of these pacemaker devices, one
could easily make appropriate adjustments for each patient.

1.3.4 Simulation flow in the Great Cardiac Vein (GVC)
Finally in chapter 5, the development of a mechanical simulation of flow
patterns in great cardiac vein (GCV) will be presented as well as future work
related to the use of implantable pressure sensors will be presented These
sensors would have to be 1) accurate, 2) small enough to fit on pacing leads, 3)
require simple electronics to function, and 4) most importantly require little
energy.
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CHAPTER II
Use of Conventional Pacemakers to Induce Atrial Fibrillation
in Dogs

2.1

Introduction
Protocols for producing experimental heart failure by rapid ventricular pacing

are well established [1]; however, for safety reasons, commonly used clinical
pacemakers do not allow pacing rates that are sufficient to induce either heart
failure (HF) or atrial fibrillation (AF). In one previous study, rapid ventricular
pacing was achieved by modifying a single-chamber pacemaker [2]. We had
been able to show how rapid pacing can be achieved without the need to modify
the circuitry or programming of a standard clinical pacemaker.
In a similar manner, experimental atrial fibrillation has been previously
induced by the use of rapid atrial pacing [3-4]. Because of the shorter refractory
period of atrial tissue, the pacing rate needs to be very rapid (400 to 600 bpm) to
induce AF. Although specially modified clinical pacemakers have been built for
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the purpose of induction of chronic atrial fibrillation [3-5], the method described
as follows facilitates AF induction without the need for pacemaker modification.
2.2

Materials and Methods
Under sterile conditions, three dogs were chronically implanted with one

endocardial lead in the right atrial appendage and another in the right ventricular
apex through the right jugular vein. Leads were tunneled subcutaneously toward
the interscapular region. Each lead was attached to a custom “Y” adapter (Figure
1). The “Y” adapters were attached to both ports of two dual-chamber
pacemakers (Figure 1). The two pacemakers were then subcutaneously
positioned 3 to 4 inches apart so that they could be separately interrogated and

Figure 1: Photograph showing the custom adapter made for us (Oscor™,
Inc, Palm Harbor, FL).

programmed [6].
Because both ports of the ventricular pacemaker were used to apply stimuli
through one lead, the device did not have to be modified to obtain ventricular
pacing rates that are sufficiently elevated to lead to tachycardia-induced heart
failure [6].
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The atrial and
ventricular
pacemakers were
programmed

at

separate times. In
this

study

they

were not activated
at the same time.
Using

the

asynchronous
mode (DOO) of
the dual chamber
Figure 2: Schematic diagram showing the placement of the leads,
adapters, and pacemakers. Note that each lead uses a custom
adapter to use both the atrial and ventricular ports of each
pacemaker to provide two pacing pulses from each pacemaker.

pacemaker,

the

ventricles can be
paced

at

rates

sufficient to produce heart failure (180 to 240 bpm). For example, if the pacing
interval is set at twice the desired interval (500 ms) and the atrioventricular (AV)
delay (250 ms) is set such that a pacing pulse from the ventricular port fires at
exactly half this interval, the ventricles can be paced at shortened intervals (i.e.
stimulation pulses from both ports) without having to modify the clinical
pacemaker [3].
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Similarly, by using the DOO mode of the dual chamber pacemaker, both
outputs can be connected to the atrial lead through the new lead adapter, and
experimental atrial fibrillation can be induced if given sufficient time for pacing.
For example, if the rate is set just above the intrinsic sinus rate and the AV delay
of the dual chamber pacemaker is set to be sufficiently short enough, the first
stimuli from the atrial port will pace the atria. The interval between the 2 pulses
was shortened so that only a portion of the atria could be re-excited by the
second stimuli originating from the ventricular port of the atrial pacemaker. This
latter pacing paradigm (two tightly coupled stimuli) frequently initiates acute AF
rather than a rapid and sometimes sustained atrial tachycardia.
2.3

Results
Because the atrial and ventricular ports of both pacemakers were alternately

used to stimulate the heart, there could have been significant leakage current
from one port into the other port when our custom “Y”-lead adapter is connected
to both ports [6] Because pacemakers are not constant current devices, this
alternating firing from both ports could possibly deplete the battery of these
devices prematurely. We consulted the manufacturer of the pacemakers that we
were using and was informed that the input impedance of these devices is
extremely high (1 MΩ). Because the impedance of the pacemaker lead-heart
interface was always less than 1 kΏ, (approximately 500 Ώ), the leakage current
back into the device and away from the heart should be less than 1% with the
use of the “Y” adapter as previously described. In all animals, we used bipolar
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pacing for both leads. In addition, bench testing showed that the lead impedance
from the atrial port changed minimally (decreased approximately 1%) when both
ends of the “Y” adapter were connected to the ventricular port compared with the
impedance when only one end of the “Y” adapter was connected to the
ventricular port. Thus
battery life should not
be

appreciably

shortened because of
current leakage into
one port when the
other port is applying
a pacing pulse [3].
The distal end of
the atrial lead was
always placed in the
Figure 3: Schematic-timing diagram shows the effects of
activating either atrial or ventricular pacemaker alone. (Panel 1)
When the ventricular pacemaker is turned off (ODO) mode, sinus
rhythm is present. The second panel depicts what one would
expect if the ventricles are paced at 120 bpm through the atrial
port (AOO) mode. (Panel 3) If the asynchronous mode (DOO) is
used with an atrioventricular (AV) interval of 250 ms, one would
expect the response to be something like this. (Panel 4) When
the atrial pacemaker is turned off, or in the (ODO) mode, a
hypothetic sinus rhythm is displayed (sinus rhythm, 600 ms). The
fifth panel depicts what one would expect if the atria are paced at
140 bpm through the atrial port (AOO) mode. (Panel 6) If the
(DOO) mode is used with an AV interval of 100 ms, one would
expect the response to be something like this. (SR = sinus
rhythm; VP = ventricular pacemaker; AP = atrial pacemaker.)

right

atrial

appendage.

Other

activation sites in the
atria may result in AF
more

readily

(e.g.,

the pulmonary veins).
However this location

for lead placement was chosen to better assure that the distal end of the lead
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would not migrate into the right ventricle and induce ventricular tachycardia or
fibrillation because of the short coupled pacing from the atrial-ventricular ports of
the atrial pacemaker. Similarly the distal end of the ventricular lead was always
placed into the apex of the right ventricle because of the stability of this location.
After both endocardial leads were attached, lead impedances and pacing
thresholds were evaluated. At 0.5 ms pulse duration, both the atrial and
ventricular leads captured the heart at less than 1 volt. The impedance of each
lead-tissue interface was less than 1,000 ohms
All pacing to the ventricles was applied through bipolar leads. Individual
pulses were routinely initially set at 5 V, 0.5 ms. The atrial port (AOO) mode was
used to pace the ventricles at a rate sufficiently fast enough to capture the
ventricles (120 bpm = 500 ms). Once ventricular pacing was achieved, the mode
of pacing was changed to the DOO mode, and the ventricular port was activated
at a 250 ms delay (see Figure 3).
All pacing to the atria was applied through bipolar leads. Individual pulses
were routinely initially set at 5 V, 0.5 ms. In one case; atrial pacing at this
intensity resulted in some phrenic nerve stimulation. Therefore the voltage was
decreased to 3 volts and atrial pacing was maintained, still resulting in induction
of AF. Because pacing measurements were set when the dogs were conscious
and each dog had a different autonomic tone resulting in quite different sinus
rates, pacing measurement settings for each animal had to be individually set
and in some cases adjusted. The atrial port (AOO) mode was used to pace the
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atria at a rate
sufficiently
enough

fast
to

capture the atria
(range, 140 to
180 bpm). Once
the atrial pacing
was
the

achieved,
mode

pacing

of
was

changed to the
DOO mode, and
Figure 4: Diagram representing 5-second tracings of the
electrocardiogram (lead II) from a conscious dog. The first panel shows
the animal in sinus rhythm (SR). The second panel shows a paced
ventricular tachycardia which will eventually lead to heart failure (VTHF) if the ventricles were to be rapidly being paced at 240 bpm. The
third panel shows that atrial fibrillation (AF) has been acutely induced in
this same animal. The fourth panel shows that sustained AF was
induced in four weeks of paired atrial pacing as evident by the continual
atrial fibrillation for 4 additional weeks after the atrial pacemaker has
been turned off.

the
port

ventricular
was

activated at an
80 to 100 ms
delay

(see

Figure 3). The classical work of Wijffels and coworkers [4] showed that there is
electrical remodeling of the atria as AF is being produced (i.e. the atrial refractory
period decreases and sometimes necessitates a shortening of the coupling
interval).
Figure 4 contains four panels of electrocardiographic recordings from one dog
during conscious testing. In the first panel, the dog is in sinus rhythm, because
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both the ventricular and atrial pacemakers are off (or in the ODO mode). The
second panel of the electrocardiographic recording (i.e. the ventricular
tachycardia which will eventually lead to heart failure (VT-HF) demonstrates the
dog being paced for 5 seconds at 240 bpm, because the ventricular pacemaker
is programmed in the DOO mode. The lower tracking rate was set at 120 bpm
(500 ms). In addition, the AV interval was set at 250 ms. These settings resulted
in a ventricular pacing rate of 240 bpm, or a pacing interval of 250 ms, with this
adapter and the dual output ventricular pacemaker. Then the ventricular
pacemaker was turned off (ODO) mode. In all three animals, the ventricular
pacemaker was not left in the DOO mode for more than 5 to 10 minutes. The
purpose here was to show how heart failure could be induced if the pacemaker
had been left on.
The third panel illustrates how AF can be induced when the atrial pacemaker
is programmed in the DOO mode [6]. In this particular case, the rate is set above
sinus rate at 140 bpm to capture the atria. In addition, the AV interval is set at
100 ms in this case (note the pacing artifacts in the tracing). The arrow shows
two stimuli separated by 100 ms. Thus, the second paced beat from the
ventricular port of this atrial pacemaker stimulates the atrial tissue when only a
portion of the atrial tissue appears to be excitable, a condition which leads to AF.
Both the pacing rate and the AV interval can be readily modified as the atria
undergo electrical remodeling to perpetuate the AF. We periodically turned off
the atrial pacemaker to evaluate whether the heart would spontaneously return to
sinus rhythm. In this particular animal, after 2 weeks of pacing sinus rhythm
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returned within 20 minutes when the pacing was stopped. After 4 weeks of atrial
pacing, the atrial pacemaker was turned off and sustained AF continued for
another 4 weeks (bottom panel). Because of the more rapid pacing rates used
and the increased pacing stimulus intensity, battery life had decreased by
approximately 3 months. However, this is a small portion of the total battery life

Figure 5: Tracings of the electrocardiogram (lead II), the right and left ventricular electrograms
(RVE and LVE) and right atrial electrogram in the same anima. The animal was in persistent
atrial fibrillation for 12 weeks after the atrial pacemaker had been turned off.

for a commercial pacemaker.
After 16 weeks of persistent AF (as the pacemaker had been turned off for 12
weeks), the pacemakers from the previously described animal were explanted
during an acute experiment. Figure 5 shows the tracing of the right atrial
electrocardiograms as well as 2 ventricular electrocardiograms and lead II. Note
the rapid erratic activity of the atria found in AF is still present (i.e., right atrial
electrocardiograms). The ventricular cycle length is regular in this part of the
experiment because we were pacing both ventricles at a cycle length of 400 ms.
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2.4

Discussion
The major finding of this study [6] is the observation that using a custom “Y”-

lead adapter, an unmodified dual chamber clinical pacemaker can be used to
achieve almost any combination of an experimental stimulation paradigm.
For more than 20 years it has been known that rapid ventricular pacing can
result in ventricular dysfunction and eventual heart failure [1-2, and 7]. In these
studies, the pacing interval was held constant for various prescribed times. The
time needed to produce tachycardia-induced heart failure is for the most part a
function of the average pacing rate [1 and 7] (i.e. the faster one paces the heart,
the faster heart failure symptoms develop). However, the time needed to develop
heart failure for a given pacing rate is variable from animal to animal and
therefore, sometimes it is unpredictable. Furthermore, many investigators
monitor cardiac functional measurements, such as ejection fraction and vary the
time of pacing to produce a more uniform state of heart failure. In a recent study
[7], the investigators found that pacing at a slower rate for a longer period of time
resulted in a model of heart failure that was more stable after the pacing was
stopped. The purpose of this study had been to show how (with the use of a
custom “Y”-lead adapter) rapid ventricular pacing at almost any rate can readily
be accomplished without modification of the pacemaker or the rapid depletion of
its battery. With the ease of programming commercial pacemakers, pacing
measurements can readily be modified to fit the goals of a variety of protocols.
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In the same manner, persistent AF can be induced by use of electrical rapid
atrial stimulation [3-5]. These atria can be stimulated using either periodic bursts
(i.e. when sinus rhythm is sensed) or using a very rapid but constant stimulus
paradigm. Both of these methods required modification of clinical pacemakers
and they greatly increased battery life consumption. Battery consumption is a
function of the pacing rate, pulse amplitude, and duration, as well as whether or
not the monitoring functions are turned on. In the representative animal
previously described, the battery life of the atrial pacemaker was decreased by 3
months, even though the atrial pacing was continued for only 1 month. With
lower stimulus intensity in the pacing pulses, it might have been possible to
somewhat extend battery life; however, that may have resulted in the need to
pace the animal for a longer period. Increased battery life consumption is
primarily due to the higher than normal pacing rate (compared to that which is
used clinically) and increased intensity of pacing, rather than the current leakage
into the other port of the pacemaker. Despite our higher consumption settings,
commercial pacemakers have the capacity to provide these pacing paradigms
many times longer than needed.
Although the induction of AF by rapid pacing results in electrical remodeling of
the atrial tissue and a shortening of the effective refractory period of the atrial
tissue [4], both the pacing rate and the AV interval of the dual chamber
pacemaker are readily adjusted to assure that the stimuli from the ventricular port
of this atrial pacemaker perpetuated the AF. All of our animals eventually
developed persistent AF. We continually paced for 4 to 5 weeks to insure that the
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animals did not revert back to sinus rhythm once the pacemaker was turned off.
In addition to our electrocardiographic measurements, we never observed the
normal mitral inflow patterns seen in sinus rhythm while performing our weekly
echocardiograms when the atrial pacemaker had been turned off.
In prior studies, persistent AF occurred only after structural remodeling of the
atria had occurred [3-4 and 8-10], a phenomenon that generally occurs long after
electrical remodeling. Thus, pacing may have to be applied for several months.
For some unknown reason, our three animals remained in persistent AF after a
shorter period of pacing. Even if the process should take 3 to 4 months, the
battery of a conventional dual pacemaker should be adequate for the induction
process. In a prior study, a modified atrial pacemaker was left on continuously in
ensure that sinus rhythm would not return [6]. This could be done using our
technique [6].
Because clinical leads and pacemakers are rugged, readily implantable,
and can provide pacing for extended periods of time, they are ideal for these
types of experiments. Thus, our present study [6] shows how with the addition of
a “Y”-custom lead adapter, an unaltered dual-chamber pacemaker, and some
imagination, AF or heart failure can be induced in a large animal model when
given sufficient time.
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Chapter III

Coupled Pacing Reverses the Effects of Atrial Fibrillation on the Left Ventricle

3.1

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the
United States [1]. By increasing ventricular rate, AF can cause a tachycardiamediated cardiomyopathy. Recent studies have shown that when sinus rhythm
can not be restored, ventricular rate control is a viable treatment option [2]. For
the last several years, our laboratory has been investigating the implementation
of coupled pacing (CP), a novel pacing paradigm, for controlling ventricular rate
of mechanical contraction (VRMC). CP involves application of electrical stimuli to
the ventricles after the effective refractory period. In previous studies [3-5], we
reported that acute application of CP resulted in both a negative chronotropic
(mechanical not electrical rate) and a positive inotropic response during acutely
induced AF. VRMC reduction by CP is the result of blocked conduction of rapid
supra-ventricular activations to the ventricles during AF. When CP slowed the
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VRMC, stroke volume increased markedly as a result of moderate increases in
left ventricular end diastolic volume and a decrease in end systolic volume. In
addition, the positive inotropic effects of CP (resulting from postextrasystolic
potentiation) increased LVdP/dt and LV ejection fraction. The purpose of this
study [6] was to determine if the hemodynamic benefits of sustained CP could be
maintained in the setting of persistent AF.

3.2

Methods

3.2.1 Surgical Preparation
The experimental protocol was approved by the Animal Research Committee
of the Cleveland Clinic. All animals used in this study received humane care in
compliance with the “Guide for the Care and Use of Laboratory Animals”
published by National Institutes of Health. The Cleveland Clinic’s Animal Care
facility is accredited by the American Association for the Accreditation of
Laboratory Animal Care.

Six mongrel dogs (20-30 kg) were included in this

study.

3.2.2 Conscious Testing
All animals were trained to lie on a couch on their left side for
echocardiographic examination.

Echocardiographic data were acquired

(Sequoia™, Seimens System with a 3MHz probe) at 1) baseline during sinus
rhythm, 2) after persistent AF but just before the beginning of CP therapy and 3)
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after 3-4 weeks of continual application of CP. LV end systolic and diastolic as
well as left atrial (measured at end systole of LV) volumes were computed from
standard apical views (2 and 4 chamber views) by using the Simpson biplane
method. Left ventricular ejection fraction (LVEF) was calculated from these
measurements [(EDV-ESV)/EDV]. Measurements from three cardiac cycles were
averaged for all volumes and these mean values were expressed as a single
value. The surface ECG was recorded during conscious testing via a Dataq™
acquisition system. Origin® plotting software was used to plot representative
ECG traces and other results.

3.2.3 Pacemaker Implantations and Pacing Protocols
Under sterile conditions, dogs were chronically implanted with 2 endocardial
pacemaker leads, one placed in the right atrial appendage and the other in the
right ventricular apex. As previously described [7], two standard dual chamber
pacemakers were used for each animal. Each device used a custom Y lead
adapter (Oscor™) in order to induce AF and to apply coupled pacing. With a Yadapter, we connected the atrial pacemaker lead to both the atrial and ventricular
ports of a dual chamber pacemaker. Similarly, the ventricular lead was
connected to a second dual chamber pacemaker via a second Y-adapter. The
Y-adapter permitted us to use both the atrial and ventricular ports of a dual
chamber pacemaker to either pace (DOO mode) the heart via one lead, or to
sense the intrinsic electrical activation of the heart via the atrial port and then
apply a paced beat via the ventricular port (DDD mode). Both pacemakers were
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implanted subcutaneously, positioned sufficiently far apart that they could be
separately interrogated and programmed.
After animals had fully recovered from pacemaker implantation surgery, rapid
right ventricular pacing was applied at a rate of 240 bpm using the DOO mode of
the ventricular pacemaker. The lower tracking rate was set at 120 bpm and the
AV interval was set at 250 ms, as previously described [7]. Ventricular pacing
was continuous at 240 bpm for two weeks. Rapid ventricular pacing promoted
ventricular dysfunction and atrial fibrosis that accelerates the development of
persistent AF [8].

3.2.4 Echocardiography
Cardiac function was assessed using echocardiographic imaging when the
pacemakers were turn off. When LVEF was reduced by approximately 20% from
the baseline value during normal sinus rhythm, the ventricular pacemaker was
programmed off (from DOO to ODO). At this time, the atrial pacemaker was
programmed in AOO mode to pace the atria at a rate approximately 20 bpm
above sinus rate. The mode of the atrial pacemaker was then switched to DOO
and the AV interval setting was adjusted to an interval sufficiently short that
stimuli from the ventricular port would still capture atrial tissue.

This pacing

paradigm eventually induces persistent AF [7]. The AV interval varied from 80 to
120 ms, depending on the individual animal and its autonomic state. Weekly
ECG measurements were obtained in order to confirm that the atrial pacing
continually fibrillated the atria. During the induction of AF, echocardiographic
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assessments of left ventricular function were continued until the ejection fraction
was reduced by approximately 30% from baseline levels. Then the atrial
pacemaker was turned off and the animals remained in atrial fibrillation.
Coupled pacing was initiated through the use of the ventricular pacemaker
programmed in DDD mode once ventricular dysfunction had developed and
persistent AF was established (after ventricular and then atrial pacing, 6-8 weeks
total). The lower tracking rate of ventricle pacemaker was set at 30 bpm and the
upper tracking rate was set at 180 bpm.

As in our acute experiments, the

individual coupling interval was adjusted for each animal. With the use of the
DDD mode of the ventricular pacemaker, the AV interval was adjusted to alter
the CP time delay to intervals ranging from 160-220 ms. Time delay adjustments
were made while monitoring LV contractions via echocardiography such that
virtually no secondary contractions were observed [5].
Analysis of variance was used to determine if any of echocardiographic
measurements (LVEDV, LVESV, LVEF, and LAV) were significantly changed [6].
In addition, we measured the ventricular rate of mechanical contractions (VRMC)
as previously described [5]. These continuous variables were expressed as
means±SE. Paired comparisons were made between these 3 periods, i.e., BL
vs. AF, AF vs. CP and BL vs. CP (Fisher LSD). A probability of < 0.05 was
considered significant.
3.3

Results
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Figure 6: ECG tracings of one dog taken during the 3 periods of this study. The top panel
shows when the animal was in sinus rhythm. The number indicates the intrinsic electrical
activations. The middle panel show when the animal was in persistent AF. The bottom panel
shows coupled pacing.

Figure 6 displays representative ECG tracings of one dog during the three
phases of this study [6]. The top panel shows normal sinus rhythm prior to the
induction of persistent AF. The middle panel show persistent AF just prior to the
application of CP. The bottom panel shows that AF persisted even after CP had
been applied for 4 weeks. The numbers above each R wave indicate intrinsic
electrical activations that resulted in mechanical contractions. The CP stimulus
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following each of the intrinsic activations in the bottom panel is indicated by the
stimulus artifact.
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Figure 7: The effects of persistent AF and sustained CP on left ventricular ejection fraction
(LVEF) and left ventricular rate of mechanical contraction (VRMC). The * indicates that
persistent AF significantly changed both LVEF and VCR. The # indicates that sustained CP
significantly reversed these prior changes within 3-4 weeks back toward their pre-AF values.

Persistent AF significantly increased the average VRMC (Figure 6, baseline
to AF, 103 ± 2.5bpm to 174.5 ± 14.5 contractions/min (C/m), p<0.001).

CP

brought the average VRMC back to 95.8 ± 9.2 C/m, (p<0.001). As shown in
Figure 7, LVEF was quite sensitive to supraventricular tachycardia, decreasing
from 52 ±2 to 32±4% (p<0.01) during persistent AF, and returning to 47±2%
(p<0.01) during CP.
We observed significant tachycardia-mediated LV remodeling, resulting in
both left atrial and left ventricular dilatation. All ventricular dimensions
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significantly increased as a result of persistent AF. The LVEDV increased from
62.3 ± 4.78 mL to 75.5 ± 6.65 mL (BL vs. AF, Figure 8, p<0.01). Similarly,
LVESV increased from 30.7 ± 2.57 mL to 51 ± 4.57 mL (p<0.001), and LAV
increased from 20.2 ± 3.84 mL to 34.8 ± 4 mL (p<0.01) during persistent AF
(Figure 8).

After sustained CP had been applied for 3-4 weeks, LV volumes

were significantly reduced (AF vs. CP, Figure 8) and returned toward the values
measured prior to the induction of persistent AF. The LVEDV decreased from
75.5 ± 6.65 mL to 65 ± 3.22 mL (AF vs. CP, p<0.0.5)) and the LVESV decreased

Effects of Chronic AF and CP on Cardiac Volumes
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Figure 8: The effects of persistent AF and sustained CP on left ventricular volumes (LVEDV
and LVESV) and left atrial volumes (LAV). The * indicates that persistent AF significantly
increased LVEDV, LVESV and LAV. The # indicates that sustained CP significantly reversed
the AF-induced increases in LVEDV and LVESV. Although CP reduced LAV, this change did
not reach statistical significance.

from 51 ± 4.57 mL to 34.5 ± 2.41 mL (p=0.001). The reduction in LV volumes
also resulted in a partial reduction of LAV towards baseline values, despite the
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continued presence of AF. That is, LAV decreased from 34.8 ± 4 mL to 27.7 ±
2.6 mL (p>0.05).

3.4

Discussion
The first major finding of this study [6] is that the effects of CP were sustained

for 4 weeks.

Sustained CP dramatically reduced the ventricular rate of

mechanical contraction (VRMC) and increased contractile performance (LVEF),
in a manner similar to that previously observed during acute AF. Second, the
sustained effects of CP resulted in a decrease of left ventricular volumes (reverse
remodeling) that had become dilated during the induction of persistent AF.
Reverse remodeling results in decreased wall stress.
Normally when the ventricles are electrically activated, there will be
corresponding subsequent mechanical contractions which in turn results in
ejection of blood.

However, during rapid AF this is not always the case.

Hemodynamic measurements from a prior acute experiment illustrate this point
(Figure 9). That is, the 13 electrical activations result in 9 contractions and these
contractions in turn lead to 6 ejections of blood (see the left panel of Figure 9). In
contrast, the application of CP during AF changes this relationship (see right
panel of Figure 9). The application of CP results in the blockage of every other
rapid supraventricular activation. However, since a coupled beat (no subsequent
contraction) followed each intrinsic electrical activation, the ventricular rate of
electrical activation (VREA) remained approximately the same with the
application of CP during AF as the rate of AF alone. The positive inotropic effect
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Figure 9:Hemodynamic tracings without CP (left panel) and then with CP (right panel) in a
prior acute experiment. Marks above ECG electrocardiogram tracings illustrate VREA, right
ventricular (RV) electrogram, 1st derivative of left ventricular pressure (dp/dt). Marks above the
left ventricular (LV) pressure tracings illustrate VRMC, and marks above the aortic flow
tracings illustrate VREJ

of CP via postextrasystolic potentiation now resulted in each intrinsic activation to
result in a subsequent contraction and then ejection of blood. That is, there were
12 VREAs, 6 VRMCs, and 6 ejections (note the marks above events).
In our prior work examining the effects of acute CP on acute AF [3], we found
that the rate of ventricular rate of electrical activation (VREA) changed from 135
to 226 to 225 activations / min from sinus to AF to CP. However the ventricular
rate of mechanical contraction (VRMC) changed from 135 to 197 to 112
contractions / min. Finally the ventricular rate of ejections (VREJ) changed from
135 to 136 to 111 ejections / min. Note, that without the application of CP, the
VRMC would not be one half of the VREAs, but they would have remained high.
In the present study [6], the cardiac responses to persistent AF and then to
sustained CP were somewhat different than previously observed during acute
AF. Our coupled pacing resulted in no change in the VREAs but there was a
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change in VRMC that is similar to the prior pre-tachycardia rate despite the
persistence of AF. In the current study, under persistent AF and chronic CP, the
VRMC changed from 103 to 175 to 96 contractions / min. Note, the application
of CP at a shortened delay resulted in no contractions both in our prior acute
studies (3-4) and in this present study [6].
In most cases, heart rate is defined in terms of VREA rather than VRMC. So
what is the concern of VREA vs. VRMC? In both acute and chronic conditions of
AF, CP reduces the VRMC but has little effect on VREA. In an earlier study [3],
the inotropic effect of CP via postextrasystolic potentiation now resulted in each
intrinsic activation to result in a subsequent contraction and then ejection of
blood. That is, there were 12 VREAs, 6 VRMCs, and 6 ejections (note the marks
above events).
A number of laboratories have reported that both chronic supraventricular
and ventricular tachycardia caused significant left ventricular dilation as well as a
reduction in the ejection fraction in dogs [9-12]. These studies also showed that
after the termination of this tachycardia, there was a rapid return of their ejection
fraction. However, there remained a residual dilatation in their left ventricular
volumes that eventually started to return towards pre-tachycardia levels.

In

contrast, our present study showed that the left ventricular volumes returned
back to their pre-tachycardia levels during the same time course as the ejection
fraction improved. Thus, the positive inotropic effect of our CP may be partially
responsible for the reverse remodeling as well as its negative chronotropic effect
as defined by the VRMC rather than the VREA. This reduction of left ventricular
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volumes induced by sustained CP reduces wall stress.
Heart rate, contractility and wall stress are all major determinants of
myocardial oxygen consumption (MVO2, [13-15]. Increases in both heart rate,
that is, VRMC and wall stress via ventricular volume dilation during persistent AF
leads undoubtedly increases metabolic demand and oxygen consumption. Our
present results suggest that both the reduced VRMC and wall stress caused by
persistent CP should reduce MVO2 and therefore counteract the effects of
increased contractility [13] on MVO2 that are also the result of CP. However,
additional experiments are needed to validate these assumptions.
In our present study [6], the remodeling induced by ventricular pacing and
persistent AF is the result of a uniform ventricular dysfunction, similar to that
which occurs during dilated cardiomyopathy [16]. Bi-ventricular pacing has been
shown to reverse the remodeling of the failing left ventricle [17]. Beta-adrenergic
receptor antagonists (β-blockers) can also cause reverse remodeling [18]. Both
β-blockers and CP result in slower VRMC, although via quite different means.
Whereas β-blockers are negative inotropic agents, CP has a positive inotropic
effect. Prior studies [17-18] suggest that reverse remodeling occurs when the
ventricle become more efficient.

This improvement of ventricular function

occurred as a result of either a more synchronous contraction, or by a slower rate
of contraction. In both cases, the time course required for reverse remodeling
was several months. In contrast, the reverse remodeling caused by CP here
appears to have occurred more rapidly.
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The increased rate of reverse

remodeling may be due in part to the positive inotropic effects of CP in addition
the reduced VRMC.
In summary, sustained application of CP appears to reverse the LV
dilation and functional impairment (LVEF) that resulted from LV dysfunction
during persistent AF. Therefore, following additional studies CP should be
considered as a means to achieve ventricular rate control and to improve cardiac
function in many cases of persistent AF, particularly in the presence of nonischemic

dysfunction.

Finally,

by

adding

this

pacing

paradigm

pacemaker/defibrillator device, these stimuli could be applied safely.
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Chapter IV
An Improved Cardiac Resynchronization Therapy

4.1

Introduction
Cardiac Resynchronization Therapy (CRT) has been shown to improve

symptoms and survival in patients with drug-refractory symptomatic heart failure
(HF) and conductive disturbances [1-8]. However, in AF patients, CRT can be
efficiently delivered only if the ventricular rate is controlled. If rate can not be
controlled, atrioventricular (AV) nodal ablation and implantation of a permanent
ventricular pacemaker may be required [9-10]. Therefore, we propose to apply a
supplemental stimulation to the right ventricle, coupled pacing (CP), in addition to
the standard CRT when AF occurs. For the past four years, our laboratory has
been studying the potential application of this CP for the treatment of AF when
there are no ventricular conductive problems [11-13]. In these prior cases, the
intrinsic electrical activation of the ventricles which initiated the contraction was
sensed and then an electrical stimulation (CP) was applied after the ventricular
refractory period but prior to the time that the ventricles were capable of
contracting again. CP activated the ventricles electrically resulting in retrograde
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activation of the AV node which in turn prevented rapid supra-ventricular
activation of the heart during AF.

Thus, CP slowed the ventricular rate of

mechanical contraction (VRMC) and increased LV filling. In addition, this CP
beat increases contractility via elevated intracellular calcium levels [14]. Based
on these prior works, we hypothesized that CP may be combined with
biventricular pacing (CRT+CP) to slow the VRMC and further improve
contractility to a greater extent than what has been observed by CRT alone in
patients with dyssynchronized HF and AF.

4.2

Methods
The experimental protocol was approved by the Animal Research Committee

of the Cleveland Clinic. All animals used in this study received humane care in
compliance with the “Guide for the Care and Use of Laboratory Animals”
published by National Institutes of Health. The Cleveland Clinic’s Animal Care
facility is accredited by the American Association for the Accreditation of
Laboratory Animal Care.
The dogs (n=6, body weight 22-29 kg) were initially anesthetized with
thiopental 25 mg/Kg IV and maintained with 1-2% isoflurane vaporized in
oxygen-enriched air during positive pressure ventilation. A mid-sternotomy was
performed and the heart was placed in a pericardial cradle. A custom
quadrapolar plate electrode was sutured to the right atrium and was connected to
a Grass stimulator.
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4.2.1 Pacing protocol
Rapid right atrial pacing (20 Hz, 1 ms, 3-5 V) was used to induce and to
maintain a rapid but continual acute AF after baseline measurements were
obtained in sinus rhythm. A second quadrapolar plate electrode was sutured on
the right ventricular (RV) apex and was connected to the first channel of a Bloom
stimulator. A third quadrapolar plate electrode was sutured on the lateral wall of
the LV for CRT delivery and connected to the 2nd channel of our Bloom
stimulator. The remaining 2 poles of these 3 quadrapolar electrodes were
connected to our recording system to record their corresponding electrograms.
Finally, a bipolar electrode was sutured on the inferior vena cava-left atrial
epicardial fat pad of 3 animals to stimulate the parasympathetic nerve that
innervates the AV node to slow A-V nodal conduction [15]. This nerve stimulation
allowed us to apply the CRT at a rate to be similar as the response during AF
and CRT+CP.
First, we obtained baseline measurements during sinus rhythm (step 1). Next
we simulated the effects of AF and left bundle branch block (LBBB) with 5
minutes of rapid RV pacing and acute AF via rapid atrial pacing (step 2). During
AF, the rate of RV pacing (2 ms, 2-4 mA) was increased to a rate sufficient to
prevent intrinsic ventricular activation over the AV node. This pacing paradigm
reduced ejection fraction to less than 35%. This mode of pacing resulted in LV
dysfunction [16] and dyssynchrony [17]. Then, we applied a rapid biventricular
pacing for 5 min such that the CRT rate was sufficient to pace both ventricles
directly (Step 3) without supraventricular activation. The pacing paradigm here
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would be somewhat analogous to when a pacemaker would pace the ventricles
rapidly by continually tracking atrial activity.

Clinically, the biventricular
pacemakers that are in an

Experimental protocol
Sinus
Rhythm

Right atrium

Baseline
N=6

VS

tracking

mode

will

normally mode switch when

Right ventricle

Step 1
Atrial
Fibrillation

atrial

Left ventricle

atrial
Atrial pacing
N=6

rate

reaches

a

prescribed limit, that is, atrial
tracking limit. As long as AF

Step 2

RV pacing
N=6

persists, effective CRT will
not be applied.

Step 3

CRT
N=6

Next, we applied CRT
(step 4) during acute AF at

Step 4

CRT+ CP
N=6

rate close to sinus rate
CRT

CP
RR

Step 5

CRT-VS
N=3

because of the addition of
the CP.

VS

CRT+CP, which

consisted of simultaneous
biventricular pacing (2 ms,

Figure 10:
Illustrates a schematic diagram indicating
the sites of electrical stimulation applied to the heart during
2-4 mA, both channels of
the various stages of this study.

the Bloom stimulator) of both ventricles was followed by an additional stimulation
or CP (2 ms, 2-4 mA, 1st channel of the Bloom stimulator) applied only to the RV
lead after the RV ventricle refractory period.

Before we added the CP, we

increased the basic cycle length of the biventricular pacing by approximately 50
% above the level needed to pace both ventricles during AF. Then we added the
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CP beat at a delay of 250 ms. Next, we progressively shortened this time delay
until we observed by echocardiography that there was no subsequent LV
mechanical contraction resulting from the CP. Finally we extended the basic
biventricular pacing rates to be close to sinus rates such that the rates of
ventricular contractions were similar.
Finally, we applied CRT alone at a rate close to sinus rate (step 5). We were
able to apply CRT at this rate because we selectively simulated the
parasympathetic nerves that innervate the AV node (pulses = 20 Hz. 0.1ms, 10
mA).
We systematically collected the data at the end of each pacing mode as
described above with a current echocardiograph system (Vivid 7, GE
Healthcare).

For each measurement, five consecutive cardiac cycles were

acquired and all images were stored on optical disk for further analysis. LV
contractility was quantified by 1) LV ejection fraction, 2) stroke volume and 3) the
peak value of the circumferential global strain (ε-peak). LV ejection fraction (EF)
was computed from standard apical views by using the Simpson biplane method.
Circumferential global strain curve was computed by averaging the 6 segmental
circumferential ε curves derived from 2D short axis view (basal segment) by
using speckle tracking analysis (EchoPac GE Healthcare). For all ε analysis,
end-diastole was chosen as the reference time-point for each cardiac cycle.
Peak ε had been defined as strain curve, when it reached its maximum value
during the cardiac cycle. The time for each of the 6 segments to reach their peak
strain was expressed in terms of the percentage of the RR interval for that
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particular cardiac cycle because of the wide range of RR intervals for these
pacing paradigms in this study. The measure of LV dyssynchrony is the standard
deviation of percentage of the time to peak circumferential ε for each cardiac
cycle. For example, if all 6 segmental peak ε occurred exactly at the same time
in the cardiac cycle the standard deviation would be zero. Conversely if the 6
segmental peaks of ε were reached over a wide range of time, the LV
dyssynchrony would be large. Diastolic period was defined as the time duration
of the Doppler early diastolic filling velocity profile (E) during atrial fibrillation and
as the sum of E and atrial velocity waves multiplied by the duration during sinus
rhythm. This measurement also was normalized to the RR interval for each
cardiac cycle. Again, because CP does not cause contractions, this electrical
activation of the ventricles was not considered in the above calculations.
Normally distributed continuous variables were expressed as a mean ± SD.
To compare numerical data between two or several groups, paired and unpaired
student test or analysis of variance was used as appropriate. Two-tailed P-values
<0.05 were considered statistically significant. Analysis was performed using
StatView® software (Version 5.0 for Windows®, SAS institute Inc., Cary, NC,
USA).
4.3

Results
The average LV dyssynchrony during sinus rhythm was approximately 7±2%

(Figure 11A). The induction of simulated LBBB by right ventricular pacing (RV)
increased LV dyssynchrony to an average of 19±3% (p<0.0001 vs. SR). The
application of biventricular pacing (CRT) dramatically reduced this LV
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dyssynchrony virtually back to the level of sinus rhythm (SD=8± 3 %). In three
animals we stimulated selectively the parasympathetic nerves innervating the AV
node (CRT-VS). This is analogous to those LBBB patients with concurrent AF in
which their ventricular rate can be controlled by pharmacological agents such
that the CRT could be applied at a more appropriate rate. In this case, the LV
dyssynchrony was similar to that during sinus rhythm (SD = 7 ± 2%). Finally,
when we applied an additional paced beat to only the right ventricle (CRT+CP),
LV dyssynchrony did not increase (SD = 8 ± 3%).

Note the average

corresponding QRS durations were measure during these echocardiographs and
are shown for all 5 steps of this study.
During sinus rhythm, the average peak global strain was -12 ± 2% (Figure
12B) when the VRMC was 128±17cpm. With the induction of acute AF and rapid
RV pacing (VRMC=219±39cpm), the peak global strain decreased to -4 ± 2%.
The application of CRT during acute AF slightly improved peak global strain (-6 ±
3%) despite the rapid VRMC (232 ± 15cpm). The reduction in VRMC (103 ±
14cpm) during CRT-VS further improved the strain until it approached that found
in sinus rhythm (-11 ± 3%).

Finally, the addition of the CP beat (CRT+CP)

increased peak global strain to a level greater than that found during sinus
rhythm (-16 ± 2%). Note that the VRMC was 116 ± 17cpm during this pacing
paradigm.
During sinus rhythm, the average diastolic duration was 40 ± 6% of each
cardiac cycle (Figures 11C). The tachycardia of acute AF plus LV dyssynchrony
of RV pacing decreased this percentage duration to 30 ± 9% (p = 0.02 vs. SR).
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The reduction in LV dyssynchrony and rapid pacing of CRT did not improve the
percentage of diastolic duration (33 ± 8%). The reduction in rate by CRT-VS also
did not prolong the diastolic duration in relation to the cardiac cycle length (27 ±
3%). Finally, the CRT+CP pacing paradigm did increase this percentage (48 ±
6%).
Finally, the LV ejection fraction dramatically decreased from 52 ± 4% to 19 ±
6% (p<0.0001, Figure 11 D) as the result of the tachycardia and LV
dyssynchrony. The resynchronization of the rapid contractions did improve the
LVEF slightly (25 ± 6%).

Also the reduction in the ventricular rate by

parasympathetic nerve stimulation also improved LVEF (25 ± 4%). However,
once again the addition of CP to CRT (CRT+CP), improved the LVEF (51 ± 10%)
to that of sinus rhythm despite the continual acute AF.

Figure 11: Changes in LV dyssynchrony (A), global strain (B), diastolic duration (C)
and LV ejection fraction (D) during the 5 stages of this study. (*) for p<0.05 vs.
baseline, (†) for p<0.05 vs. RV pacing, (‡) for p<0.05 vs. CRT, (¥) for p<0.05 vs. CRTVS.
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4.4

Discussion
The major finding of this study is that if atrial fibrillation should occur with

heart failure patients that are utilizing CRT, the beneficial effects of CRT could
continue if the biventricular pacemaker had the capabilities of applying coupled
pacing. Normally if the atrial rate exceeds a prescribed limit, the atrial tracking by
biventricular pacemakers would stop and the pacemaker would mode switch to
VVIR. This new pacing mode results in a less effective pacing therapy than
would occur if CRT was being applied. In the present study, we demonstrated
that CRT+CP is capable of slowing supraventicular activation of the heart by half
in a similar manner as coupled pacing does when the ventricular conductive
system is intact.

As a consequence, if AF should occur, the CRT could

continually be applied at an optimal rate. Additionally, CP added to the CRT
provides positive inotropic effect. This increase of contractility and diastolic filling
provided by CRT+CP should also be considered as an option for therapy in non
responder patients with sinus rhythm in which CRT alone has not improved their
cardiac function as it does in others (responders).
In patients with severe heart failure (NYHA III-IV), depressed LV function
(EF<35%) and a wide QRS complex (QRS>120ms), the beneficial effects of CRT
have been documented with improvement of symptoms [1-8] and prognosis [8].
Reduced mechanical dyssynchrony with CRT decreases wall stress, mitral
regurgitation volume [2, 4, and 18] and increases stroke volume [18-21], LV dP/dt
[17 and 22] and ultimately leads to LV reverse remodeling [1-2, 4, and 8]. In most
cases, the beneficial effect of CRT seems effective in both sinus rhythm and AF
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patients [23].

However, efficient CRT delivery during either paroxysmal or

chronic AF required a pharmacological control of ventricular rate because CRT
devices which use an atrial tracking mode are set at an upper tracking limit to
avoid a rapid ventricular tachycardia. In drug-refractory AF patients, AV nodal
ablation with permanent pacemaker implantation or pulmonary vein ablation may
be needed [9]. An alternative therapy to these procedures would be a simple
modification of the CRT algorithm, i.e., CRT+CP, which consists of delivering a
supplemental beat after the biventricular pacing.
Published results showed that CP reduces the mechanical rate of contraction
during acute AF [11-13]. Coupled pacing differs from paired stimulation in that it
uses the spontaneous ventricular depolarization as the first of the 2 electrical
activations [14]. This intrinsic activation determines when the second of the
paired stimuli is applied. Since the second beat travel retrogradely into the AV
node and blocks approximately half of the supraventricular activation of the heart,
coupled pacing results in a rate of ventricular contraction approximately half that
which occurs prior to the application of stimulation. These techniques had been
successively used to reduce ventricular rate during ventricular tachycardia [24],
atrial tachycardia and fibrillation [11-13]. Consistent to our previous findings, we
found that CRT+CP also permitted us to apply the biventricular pacing at half the
rate that CRT alone that would have to be applied during AF. This negative
chronotropic effect of CRT+CP resulted in an increased in the diastolic period for
improved LV filling and presumably the coronary flow. In addition to the
subsequent beneficial impact of a slower heart rate, the addition of the CP beat
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appears to increase the diastolic/systolic time ratio (Figures 11C). These results
suggest CRT+CP not only increase the intracellular calcium ions supply but may
also affect the subsequent re-sequestering of this ion.
In addition to the negative chronotropic effect of CRT+CP, this new pacing
paradigm (CRT+CP) resulted in a positive inotropic effect similar to coupled
pacing.

This increase in contractility has been termed “postextrasystolic

potentiation”. The mechanism for this potentiated response is the increased
release of calcium [14].

In 1965, Ross and Braunwald [25-26] termed this

positive inotropic effect “electro-augmentation” because it was induced by
electrical pacing rather than pharmacological agents. Paired stimulation, first
proposed as a heart failure therapy more than 50 years ago, increases systolic
function of the heart [14 and 26-27]. The effects of paired stimulation are
generally achieved by applying two closely paced stimuli to the right ventricle.
However, when compared to intrinsic activation of the ventricles, continual
right ventricular pacing can be detrimental because of the dyssynchrony
produced by such a pacing paradigm [17]. Prior application of paired stimulation
has been shown to increase MVO2 proportionally to its positive inotropic effect
[25]. In addition to the dyssynchrony, paired stimulation normally is applied at a
rate equal or greater than the intrinsic rate. In contrast, when CP is applied, the
contractile rate is one half the intrinsic activation rates and CP does not induce
dyssynchrony.

As a result, we did not observe a marked increase in MVO2

during the application of CP [12]. In the present study, we did not measure the
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oxygen consumption. However, CRT+CP like CP reduces the contractile rate
and does not cause dyssynchrony as does paired pacing.
Since stimuli are applied prematurely, there is a risk that these stimuli could
induce ventricular tachycardia, which might lead to ventricular fibrillation.
However, extending the delay of coupled stimuli (less prematurely) still maintains
improved cardiac function [13].

In addition, Mischke et al [24] had recently

demonstrated that in the worst clinical situation, paired ventricular stimulation can
be safely delivered during ventricular tachycardia in patients with predominantly
ischemic LV dysfunction (17/22 ischemic, LVEF=38 ± 14%). Additionally, we
have never observed any ventricular arrhythmia with a premature stimulation
appropriately delivered as described. However, if ventricular tachycardia were
induced, the episode could be quickly terminated with a pacemaker/internal
cardiac defibrillator system. Importantly, in symptomatic heart failure patients
with severe LV dysfunction requiring an Implanted Cardiac Defibrillator (ICD), CP
could be assessed with a high degree of safety.
In acute dyssynchronized dysfunctional heart with concurrent AF, CRT+CP
slows the ventricular contractile rate and provides a greater increase in
myocardial contractility and the diastolic filling compared to CRT alone in which
the ventricular rate can be controlled by parasympathetic nerve stimulation. The
addition of a coupled beat permits the CRT to be applied at a slower and more
appropriate rate for optimal cardiac function.
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Chapter V
Simulation of Flow in the Great cardiac Vein and the Use of Sensors for
Monitoring Flow for Use in Cardiac Pacing Monitoring

5.1

Introduction
In order to effectively use pacing paradigms such as coupled pacing, it is

essential that the pacing device have some measure of the response of the heart
to this pacing other than just sensing intrinsic electrical activations. In the past,
and T. Bennett et al [1] and D. Steinhaus et al [2], had been involved in the
development

of

implantable

hemodynamic

monitoring

systems

for

the

management of heart failure patients. Bennett and his colleagues at the
Medtronic Corporation had developed the Chronicle

®

System which is an

implantable homodynamic monitor (IHM). Their IHM system comprised a monitor
(which included pressure sensing circuits and a means for storing continuous
pressure trends, pressure sensors, and a pressure data storage monitoring
device. These implantable pressure sensors had been sealed and included a
means for indicating changes in the right ventricular pressure [1]. Medtronic’s
Chronicle

®

System had been designed to be implanted in the same manner in

which pacemakers are implanted. Bennett al concluded from their IHM studies
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that their implantable hemodynamic monitor could be permanently placed in
heart failure patients.
Since the right ventricular pacing lead enters the heart via the cephalic vein,
one could measure blood flow returning to the heart via 2 pressure sensors on
this lead at the level of the superior vena cava. Although measurement would
only represent a portion of the cardiac output, this measurement should reflect
changes in cardiac output.

In those cases where left ventricular pacing is

needed such as CRT, one implants a pacing lead into coronary sinus. On this
second lead, 2 additional pressure sensors could be attached to measure
coronary sinus flow via differential pressure. I have developed 2 different mock
circulatory systems, designated as Mock I and II Circulatory Circuit which
provides a means by which the flow profiles which exist in both the great cardiac
vein (GCV) and the Superior Vena Cava (SVC) structures can be simulated in
order to confirm that the differential pressure obtained in this system is
representative of flow.
Historically, The Bernoulli Equation had been considered to be a statement of
the conservation of energy principle which is appropriate for the flow of fluids.
The Bernoulli equation [3] is shown below (the original form):
•

V2 + gh + (p/ρ) = constant Equation (1)
Where:
o (V) represents the fluid velocity at a point on a
streamline;
o (g) Represents the acceleration due to gravity,
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o (h) Represents the height of the point above a reference
plane,
o (p) Represents the pressure at the point,
o (ρ) Represents the density of the fluid at all points in the
fluid.
And the fluid must be:
•

Must be incompressible even though the pressure is varying
and the density must remain constant.

•

The streamline cannot enter the boundary layer
o A boundary layer is defined as that fluid layer that is
adjacent to the bounding surface

•

Turbulent flow occurs when the fluid particles move in a
random fashion in the (x), (y), and (z)-directions in a blood
vessel

•

And there are no viscous forces present [4].

Since the pressure sensors may move from the boundary layer and the
streamline as the heart contracts. And since blood flowing through the native
great cardiac vein (GCV) is turbulent and viscous in nature, the simulation does
take these limitations into account as will be discussed later. I can theoretically
assume that the flow as produced in our mock circulatory circuit does follow the
differential pressure as measured by the two Millar pressure sensors. And that
the Bernoulli equation is not applicable for our simulation of flow profiles in the
GVC since the fluid flowing through the mock circuit has a high viscosity and is
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undoubtedly turbulent.
This mock circulatory circuit is simulating the pulsatile flow of the great cardiac
vein through a conduit and should also be addressed in order to realistically
model flow profiles through this cardiac vein. DA McDonald discussed the
relationship that exists between the pressure gradient to the derivative of
pressure with respect to time [5]. If the distance between two points which is
represented as (Δz) is very small, this pressure gradient can be expressed after
being differentiated as:
•

(dp/dz) = (dp/dt)* (dt/dz)

Equation (2)

where:
o (dp/dz) represents the “space coefficient” with respect to
time. [5]
And if (c) is used to represent the velocity of the “pulse wave” which develops,
then equation (2) can now be written as:
•

(-dp/dz) = (1/c) (dp’dt)

Equation (3)

Since the flow rate is dependent on the pressure gradient, it is also “dependent
on the rate of change of the pulse pressure” [5]. This time derivative calculation
of flow had been with the assumption that blood as a fluid had no viscosity and
traveled through a conduit (blood vessel) without any type of distortion which has
been found not to be the case. That is blood is a highly viscous fluid and blood
flow through a blood vessel with a lot of variation since it is a pulsatile flow [5].
And as discussed by Mcdonald [5], the viscous nature of blood results in a
dampening of its “amplitude” and decreases its velocity.
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Thus the pressure

gradient as represented by Equation (3) is “directly related to flow” as stated in
the McDonald text [5]. And the factors which “modify” this pressure gradient
should be taken into account these factors, e.g. “wave reflections”, non-linear
effects, distensibility and viscosity effects, in order to more accurately represent
pulsatile flow in blood vessels.
There are some limitations of my mock circulatory circuit such the fluid used
does not have the same viscosity as blood and the fluid flow is somewhat
Newtonian whereas blood is somewhat non-Newtonian in nature. However, it
should be stated that this mock circulatory circuit (Figure 12) does approximate
the flow rate through a conduit or vessel, taking into account the flow analyses
done by Womersley and Bernoulli [5]. Also the vessels as represented by the
conduit have to be curved and this curvature changes with each contraction
since the great cardiac vein is in fact highly curved in nature. Thus, the mock
circulatory circuit simulates the flow profiles in the great cardiac vein do
approximate the pulsatile flow of blood which is related to differential pressure.

5.2

Simulation of the Great Cardiac Vein (Mock Circulatory Circuit)

1.

Simulate the flow profiles of the Great Cardiac Vein (GVC) in a mock

circulatory circuit which will simulate flow profile changes of the native GVC.
2.

Perform post-sampling techniques on the raw data obtained from

mechanical model to determine the extent of processing required to measure flow
via differential pressure using standard acceptable signal processing techniques.
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3.

Confirm that preliminary flow profile data obtained using this mock

circulatory testing system follows the differential pressure measurements obtained
from the pair of Millar pressure sensors in a linear fashion.
4.

Re-design mock circulatory circuit as necessary to improve simulation

results if aim 1 is feasible and based on 1st phase of our acute animal studies.
5.

The results of this part of my dissertation work can be used as a basis for

others to modify implantable pressure sensors which can be attached to preexisting pacing leads to optimally provide a means for adjusting the pacing
regimens in both CRT and CRT+CP pacing paradigms.
5.3

Methods

5.3.1 Bench Testing Phase I: I used the mock circulatory circuit for simulating
flow profiles in the great cardiac vein, as discussed during my Candidacy. This
mock circulatory circuit (Figure 12) is comprised of the following components: a
reservoir which represents blood flow returning from the capillary beds; a
peristaltic pump mechanism (A Harvard Systems Ventilator).

The movement of

the shaft of this pump was used to change the curvature of the tubing used to
emulate the movement of the GCV during ventricular contraction as well as
provide a pulsatile flow.

A flow probe; a screw clamp which represents the

thoracic cavity’s pressure change; a flow meter; two Millar pressure transducers,
for obtaining a differential pressure; and a DATAQ Data Acquisition System for
digitalizing all analog signals obtained for performing post sampling analysis. All
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data collection had been obtained using the DATAQ D1-720 Hardware and
WINDAQ acquisition software.
Prior to the collection differential pressure and flow data, all mock circulatory
circuit components had been calibrated, i.e. the flow meter and both Millar
transducer boxes both calibrated and balanced. Separate experimental trials of
flow data were collected over a period of 5 minutes for each individual run. The
sample rate was set at 3000 (actual computer sample frequency had been
2999.625) for the three recording channels with a moving average value-set to a
value of 50. DATAQ’s moving average algorithm involves the use of a smoothing
factor. More specifically, this algorithm allows one to specify the number of actual
waveform data points or samples that the moving average will span. It
accomplishes a moving average by taking two or more of these data points from
the acquired waveform, adding them, dividing their sum by the total number of
data points added, replacing the first data point of the waveform with the average
just computed, and repeating the steps with the second, third, and so on data
points until the end of the data is reached. This results in the generated
waveform to consist of averaged data which has the equivalent number of data
points as the original waveform had. It should also be noted that the distance
between the two Millar sensors had been measured to have a length of 3.0
centimeters. And the distance between the end of the 2nd Millar sensor and flow
probe had been set at 5 cm.
Based upon the work of Cohen [6] and the preliminary results of D. Wallick et
al, I completed the development of a mechanical mock circulatory system that
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generated both flow and pressures similar to that measured in the great cardiac
vein of dogs. This was achieved by means of changing the stroke volume of a
pulsatile pump, changing the curvature of the tubing (“GCV”) and altering the
outflow resistance of this system. Since the great cardiac vein is located around
the circumference of the base of the left ventricle, the vessel undergoes a
significant amount of movement during normal contraction. I collected initial
simulated GVC Flow Profiles to determine that that the flow produced by the
Mock Circuit does follow differential pressures obtained by the two Millar
pressure sensors. I then confirmed that the flows produced by the mock
circulatory circuit are representative of the approximate baseline flow
measurement for the GVC, as determined by Cohen et al [6], i.e. 42.9 +/- 4.1
ml/min.
2nd Phase of Bench Testing Phase: In two separate experiments I used
markedly different construction of leads in which the pressure sensors could be
mounted.

In the first series (Mock I Circuit as shown in Figure 13), I used

sensors that had been mounted on a very flexible catheter system.

In the

second series of experiments (Mock II Circuit as shown in Figure 14), I used a
stiffer catheter system in to ensure that I had effectively changed the arc of the
great vein system and substituted in a Gilson Minipuls 2 Peristaltic Pump in place
of the A Harvard Systems Ventilator in order to remove any negative pressures
that had been observed in my Mock I Circuit. The purpose of the second series
of experiments is to determine how pressure measurements would have to be
obtained in order to accurately reflect the flow within the simulated vessel. This
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was the worst-case scenario, in which pressures measurements would be
affected by the movement of the heart. In the first two series of experiments, I
used water as a medium to measure blood flow.

In the second group of

experiments I used a medium that would better emulate the viscosity of blood
(ethylene glycol). These experiments would be used as a basis for re-designing
my Mock Circulatory Circuit to obtain more accurate and precise GVC flow
profiles. Once the appropriate modifications were made to my mock circuit,
simulated flow profiles had been collected as well as performing both post
sampling and statistical analysis on this phase of simulated flow profile data
(Table II) to optimize the results.
Mechanical simulation of blood flow in the great cardiac vein:

Using a

pulsatile pump, a Windkessel capacitor, and a flexible tube that is distorted in a
similar manner as occurs to the cardiac vein during ventricular contraction, I have
simulated the pressure and flow characteristics of blood in the great cardiac vein
of a dog’s heart using the Mock Circulatory Circuits as illustrated in Figure 13-14.
The mock circulatory testing system as shown in this Figure 12 comprised the
following components: a reservoir (A) which will include a roller pump; a
peristaltic pump or roller pump (B) which is representative of the torsional motion
of the heart caused by the pressure sensors moving within the coronary vessels;
a differential torque mechanism (C) which is representative of the torsional force
changes of the heart itself; a flow probe (D); a screw clamp (E) which represents
the thoracic cavity’s pressure change; a flow meter (F); two pressure transducers
(G) and (H), respectively, for obtaining a differential pressure as illustrated by (I);
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and Data Acquisition System (DAQ) represented as (J). With 2 Millar pressure
sensors for measuring cardiac vein flow and an extracorporeal flow probe for
comparison, I was able to determine that measurements of differential pressure
will adequately measure flow in this system (refer to Table II).
5.3.2. Experimental methods/tools (Mock I and II Circuits):
1.

DATAQ® Software with WINDAQ/XL add-on software

2.

(2) Millar pressures sensors

3.

Acquisition period for each trial (5 minutes)

4.

Origin® plotting software
Table I: Experimental protocol for Data Acquisition
Channel Number (#)

Channel Designates

Pressures from 1st pressure sensor
Pressures from 2nd pressure sensor
Flow being recorded
Smoothed data from 1st pressure sensor
Smoothed data from 2nd pressure sensor
Channel # 4 – Channel #5
Smoothed data from channel #3

#1
#2
#3
#4
#5
#6
#7

DAQ System (J)

Flow Meter (F)
Differential Pressure (I)

Flow
Probe (D)

Pressure
Pressure Transducer
Transducer # 1 (G)
# 2 (H)
Screw
Clamp (E)

Differential
Torque

Peristaltic
Pump (B)

Reservoir (A)

Figure 12:

Schematic of components for simulation of the flow
in the great cardiac vein (GVC).
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Figure 13:

Photograph of the Mock I Circulatory Circuit.

Figure 14: Photograph of the Mock II Circulatory Circuit.
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Figure 15: Photograph which shows an actual recording of differential pressures as
recorded by 2 Millar Pressure Transducers for two recording channels using the Mock II
Circuit and DATAQ software.

5.4

Results (Mock II Circuit)
Origins plotting software for data which obtained for 20 seconds using the

Mock II Circuit is shown in Figure 16. From this origin plot, it can be concluded
that flow does follow differential pressure as measured by a pair of Millar
pressure sensors. DATAQ® software with WINDAQ/XL, which is a software addon to WinDaq (DATAQ® Instrument), had been used to as a post-sampling
analysis tool for establishing the foundation for future acute studies. Note that
only results obtained from the Mock II circuit (Figure 16) will be presented. As
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was discussed earlier, I had made changes to the 1st mock circulatory circuit to
develop a more realistic simulation of flow profile in the GVC, e.g. used a stiffer
catheter system in order to ensure that the position of the catheter and therefore
the pressure sensor moved as the simulated contraction occurred. The plots as
shown in (Figure 16) had been obtained using the Origin plotting software;
illustrates the relationship between the changes in pressure vs. flow. Several
experimental runs using the Mock II Circuit (Figure 14) had been performed and
the plots of some of these trials had been presented in these figures. Figure 32
as shown is a photograph illustrating an actual recording of differential pressures
as recorded by 2 Millar Pressure Transducers for two recording channels using
the Mock II Circuit and DATAQ software. Table III illustrates the statistical
analysis for two of the experimental trial runs using the Mock II circuit.
Table II Illustrates the Statistical Analysis for Two Trial Runs
DATE
PERFORMED,
TRIAL #,
8-20-07, #3
9-2-07, #15

X VARIABLE

Y VARIABLE

ST. DEV

P VALUE

R VALUE

Flow (ml/m)

NUMBER
OF DATA
POINTS
20181

Change in
Pressure
(mmHg)
Change in
Pressure
(mmHg)

14.057

< 0.0001

.74156

Flow (ml/m)

20095

14.529

< 0.0001

.79073
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5.5

Conclusions
Our prior results [7-9] demonstrate that an effective treatment of AF and heart

failure results in an increase in the ratio of external cardiac work to myocardial
energy consumption, i.e. an increase in myocardial efficiency [8]. This ratio can
be increased if the cardiac work is preserved or increased while the therapy
decreases the total amount of energy used by the heart. In contrast, the
efficiency of the heart diminishes if the heart uses energy that does not lead to
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C h a n g e in P re s s u re (m m H g )

Figure 16: Change in Pressure vs. Flow for Trial #3 on 8-20-07. Note the
blue line represents the linear fit performed.

external work. One such example occurs during AF when the rapid ventricular
activations result in isovolumic contractions that result in no ejection of blood
from the heart, thus no external work. Prevention of partial isovolumic
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contractions would stop the use of energy that results in no external work, thus
increasing the efficiency of the heart. It has been previously demonstrated that
CP prevents these non-ejecting beats and increases the heart’s mechanical
efficiency [7-8]. In order to obtain these values, one would normally have to
measure ventricular pressures and volumes as well as myocardial oxygen
consumption.

There are now pacemaker systems that can measure right

ventricular pressure [1]. Our work indicates that CP does not significantly alter
mean systemic pressure. However, the measurement of both changes in and
absolute ventricular volumes values can be quite difficult to obtain. Thus, the
measurement of external cardiac work would be challenging in the clinical
setting.

Next, the durability of oxygen sensors and their ability to measure

coronary sinus oxygen content is questionable. In addition, in order to measure
myocardial oxygen consumption, one has to measure coronary blood flow as well
as the extraction of oxygen. However, our previous results indicate that changes
in coronary blood flow parallels the changes in myocardial oxygen consumption
[8]. That is, the extraction of oxygen from the heart remains relatively constant
despite changes in metabolic demand. Therefore, the short-term changes in
coronary blood flow generally indicate corresponding changes in myocardial
oxygen consumption, a measure of total energy used by the heart.
Based on both the bench trials and the previous work, a modified ratio of a
portion of cardiac output to coronary sinus blood flow appears as the most
feasible cardiac parameter that could be used as a control system to provide
optimal pacing. Since it is standard practice to secure a ventricular pacing lead to
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the right ventricular apex via the cephalic vein for ventricular pacing, one could
measure blood flow returning to the heart via a proximal flow sensor on this lead
in the superior vena cava. Although measurement would represent only a portion
of the cardiac output, it would be a simple representative measurement of cardiac
output. In those cases where left ventricular pacing is needed, one could implant
a pacing lead into the coronary sinus, now a standard clinical practice for
biventricular pacing. On this second lead, an additional flow sensor could be
attached to measure coronary sinus flow.

Also 4 of these sensors could be

incorporated onto the lead that enters the great cardiac vein (see Figure 17). By
periodically determining the ratio of “cardiac output” to coronary sinus flow, one
could determine if this index of cardiac efficiency changes. Then based on the
changes in this index, the pacing algorithm could be adjusted. In order to validate
that this ratio is the best cardiac parameter to use in our control system, we could
compare this proposed index to other standard measurements such as average
ventricular rate and right ventricular pressure.

5.6

Future Work

There is the potential for using implantable pressure sensors as shown in
(Figure 17) for optimizing either CRT and or our novel pacing paradigm
(CRT+CP). Future acute animal studies could involve comparing the responses
of predetermined sensors, e.g. implantable pressure sensors in the GVC and
SVC veins (Figures 17) which provide a means for measuring cardiac output and
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coronary sinus blood flow. As flow is increased in the great cardiac vein or the
superior vena cava vein, the differential pressure (GCV1 – GCV2) or (SVC1 –
SVC2) would change the balance of the Wheatstone bridge circuit configuration.
If the changes are similar the balance would remain the same. But if flow is
increased proportionally at a greater value in the GVC than in the SVC, there
would now be a change which reflects that the heart’s efficiency is decreasing.
Thus the appropriate changes could be made to optimize cardiac pacing in heart
failure patients.
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In order test our hypotheses and compare the sensors, we could adjust the
time delay for CP and CP+CRT in order to obtain the maximal efficiency index
under conditions similar to those described in previous work [4]. We could use
this

Figure 17: A diagram of our proposed new biventricular pacemaker .with our
new ventricular pacing leads. Note the 2 Xs on the right ventricular lead. They
indicate the 2 pressure sensors located in the superior vena cava that would
measure a portion of venous return “cardiac output”. Similarly note the 2 Xs on
the left ventricular pacing leads. These sensors are located in the great cardiac
vein and would be used to measure coronary blood flow.

value of efficiency as a set point and then use a negative feedback control
system to monitor deviations from the set point with our sensors. Our control
system could then adjust the values toward the predetermined set point values
for the purpose of varying the pacing parameters within clinically acceptable
ranges. Most likely, we would change the time delay of the stimuli and/or apply
the stimuli intermittently as needed. Post-sampling techniques could then be
used to determine the optimal set points.
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